Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
13 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06252753 | Observational Study Protocol: LIVER-R(LIVER-R) | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT07065344 | A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region(DOMAIN) | recruiting | — | 500 | AstraZenecaINDUSTRY | 10 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT07647328 | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer(SERAFA-1) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 9 | Sep 8, 2026 | clinicaltrials |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | recruiting | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 3, 2026 | clinicaltrials |
| NCT07650773 | CHARM Hepatocellular Carcinoma MEA Study | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT05443126 | A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | recruiting | Phase 1 / Phase 2 | 265 | Ellipses PharmaINDUSTRY | 8 | Jul 1, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT04289935 | Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer(VISION I) | recruiting | N/A | 420 | Klinik Hirslanden, ZurichOTHER | 4 | Oct 23, 2024 | clinicaltrials |
| NCT03225586 | Prospective Urban Rural Epidemiology Study(PURE) | recruiting | — | 200,000 | Population Health Research InstituteOTHER | 25 | Jan 31, 2024 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials